Dr. Agarwal's Health Care Limited confirmed on September 29, 2026, that Orbit Healthcare Services Nigeria Ltd has become a step-down wholly owned subsidiary through Orbit Healthcare Services (Mauritius) Limited.

The development follows an intimation received from Orbit Mauritius, which is a direct wholly owned subsidiary of the company. Consequently, the Nigerian entity is now both a wholly owned subsidiary of Orbit Mauritius and an indirect step-down wholly owned subsidiary of Dr. Agarwal's Health Care Limited.

Regulatory Disclosure

The company filed this update with BSE and NSE under Regulation 30(7) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure serves as a continuation of an earlier letter dated August 4, 2026, regarding the proposed establishment of the step-down subsidiary in Nigeria.

Corporate Structure Update

The confirmation solidifies the corporate structure involving the company's international operations. The key entities involved in this structure are outlined below:

The company stated that it has received formal confirmation regarding the completion of this corporate action. The filing was signed by Thanikainathan Arumugam, Company Secretary and Compliance Officer, on September 29, 2026.

Dr. Agarwal's Health Care Limited announced the cessation of Sanjay Anand as an Independent Director effective September 29, 2026. The departure follows the completion of his second term of five consecutive years, in compliance with statutory tenure limits.

The company filed a disclosure with BSE and NSE citing Section 149(11) of the Companies Act, 2013 and Regulation 25 of the SEBI Listing Regulations. These provisions mandate that an independent director cannot serve more than two consecutive terms. Anand’s tenure concluded at the close of business hours on the filing date.

Committee reconstitution

Following Anand’s exit, Dr. Agarwal's Health Care Limited revised the composition of its Board committees to ensure continued compliance with governance norms. The Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee, Corporate Social Responsibility Committee, and Risk Management Committee have been reconstituted with new chairpersons and members.

The updated committee structures are detailed below:

Governance implications

The reconstitution maintains a majority of independent directors across key oversight committees, including Audit and Risk Management. This structure aligns with SEBI requirements for listed entities to ensure robust internal controls and stakeholder protection. The board expressed gratitude for Anand’s guidance during his tenure.